Researchers evaluate expanding health benefits of GLP-1 medications

GLP-1 receptor agonists, initially developed to treat type 2 diabetes and later obesity, are now being examined for a range of additional health effects. Clinical trials have shown that the drugs can lower the frequency of breathing interruptions in patients with moderate-to-severe obstructive sleep apnea and reduce liver inflammation and fibrosis in individuals with metabolic dysfunction-associated steatohepatitis. Researchers also cite strong randomized-trial evidence for kidney-protective benefits.

Experts note that weight loss driven by GLP-1 therapy contributes to many of these improvements, but some effects may be independent of weight reduction. "There are probably both weight-dependent and weight-independent effects," said Dr. Melanie Jay of NYU Grossman School of Medicine. Dr. Louis Aronne of Weill Cornell Medicine added that activation of GLP-1 receptors in blood vessels can increase nitric oxide production, helping vessels relax and reducing cellular damage.

Small studies suggest the drugs might lessen alcohol cravings by acting on brain reward pathways, though the magnitude of benefit varies. Potential impacts on fertility, cancer risk and other addictions are still under investigation, and scientists caution that observational links do not prove causation. "Cancer claims are perhaps where we need the most caution," Dr. Jay said.

While the medications are generally well tolerated, they can cause side effects, are costly, and do not work uniformly for all patients. Dr. Robert Kushner, a founder of the American Board of Obesity Medicine, emphasized the need for further research to identify which patients benefit most, at what dose and for how long. "While all GLP-1 medications still gain FDA approval through the regulatory pathways of weight management or as a treatment for diabetes, their effects certainly transcend these two medical conditions," he said.